Avrobio halts PhII study for Fabry disease in another setback, shuttering lead program

Max Gelman

Senior Editor

An oft-troubled Fabry disease program got the axe Tuesday as its parent company will shut down development after reviewing some new Phase II data. And …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Avrobio halts PhII study for Fabry disease in another setback, shuttering lead program

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA lifts hold on Entrada's Duchenne drug after two years

How AI can address ongoing challenges in the life sciences industry

Avro­bio halts PhII study for Fab­ry dis­ease in an­oth­er set­back, shut­ter­ing lead pro­gram

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Avrobio halts PhII study for Fabry disease in another setback, shuttering lead program